Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib. (April 2017)

• Record Type: Journal Article
• Authors: Giovanis, Petros; Pianezze, Graziano; Vincenzi, Valter; Manuppelli, Carla; Boaretto, Massimo; Pastorelli, Davide
• Is Part Of: Hepatic oncology. Volume 4:Number 2(2017)
• Page Start: 39
• Page End: 43
• Publication Date: 2017-04
• Subjects: angiogenesis inhibitors -- CECs -- hepatocellular carcinoma -- sorafenib; Liver -- Cancer -- Periodicals; 616.99436005
• DOI: 10.2217/hep-2016-0011
• Languages: English
• ISSNs: 2045-0923

Abstract

Aim: We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP).Materials & methods: CECs in advanced HCC patients receiving sorafenib were counted at baseline and every 4 weeks.Results: Twenty four HCC patients were enrolled in the study. Median TTP was 3.2 months (1–6). Median baseline CEC levels were 67 cells/ml, with an increase of 169.8% after 4 weeks of treatment. Any time CEC levels in patients with a TTP lower than 4 months were higher, but not statistically significant, compared with those in patients with TTP more than 4 months.Conclusion: Treatment with sorafenib changed CEC levels in HCC patients.